{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:00:30Z","timestamp":1793174430864,"version":"4.5.0"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101,080,611"],"award-info":[{"award-number":["101,080,611"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ejpb.2025.114637","type":"journal-article","created":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T02:05:34Z","timestamp":1737252334000},"page":"114637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Excipients in drug delivery systems: A comprehensive review of approved inactive ingredients for human ophthalmic formulations"],"prefix":"10.1016","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0442-6730","authenticated-orcid":false,"given":"Raquel Gregorio","family":"Arribada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Rodrigues-Braz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Silva-Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Behar-Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejpb.2025.114637_b0005","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/17425247.2019.1618829","article-title":"Expert opinion on drug delivery recent advances in slow and sustained drug release for retina drug delivery Recent advances in slow and sustained drug release for retina drug delivery","volume":"16","author":"Behar-cohen","year":"2019","journal-title":"Expert. Opin. Drug Deliv. [Internet]"},{"key":"10.1016\/j.ejpb.2025.114637_b0010","volume":"14","author":"Arribada","year":"2022"},{"key":"10.1016\/j.ejpb.2025.114637_b0015","article-title":"Biodegradable polymer-based drug-delivery systems for ocular diseases","volume":"24","author":"Tsung","year":"2023","journal-title":"Int. J. Mol. Sci.. Multidisciplinary Digital Publ. Inst. (MDPI)"},{"key":"10.1016\/j.ejpb.2025.114637_b0020","series-title":"Drug Development and Industrial Pharmacy","first-page":"513","article-title":"Special focus issue: Ocular and ophthalmic drug delivery systems","author":"McConville","year":"2016"},{"key":"10.1016\/j.ejpb.2025.114637_b0025","series-title":"International Journal of Pharmaceutics","article-title":"Recent advances in ophthalmic preparations: Ocular barriers, dosage forms and routes of administration","author":"Maulvi","year":"2021"},{"key":"10.1016\/j.ejpb.2025.114637_b0030","series-title":"Therapeutic Advances in Ophthalmology","article-title":"Nanotechnology-based formulations to amplify intraocular bioavailability","author":"Kagkelaris","year":"2022"},{"key":"10.1016\/j.ejpb.2025.114637_b0035","doi-asserted-by":"crossref","DOI":"10.2174\/187221110789957246","article-title":"Recent advances in developing ophthalmic formulations: a patent review","volume":"4","author":"Lu","year":"2010","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"10.1016\/j.ejpb.2025.114637_b0040","volume":"14","author":"Wang","year":"2022"},{"key":"10.1016\/j.ejpb.2025.114637_b0045","first-page":"1","volume":"12","author":"Mazet","year":"2020"},{"key":"10.1016\/j.ejpb.2025.114637_b0050","series-title":"British Journal of Pharmacology","first-page":"4205","article-title":"Principles of pharmacology in the eye","author":"Awwad","year":"2017"},{"key":"10.1016\/j.ejpb.2025.114637_b0055","series-title":"Therapeutic Advances in Ophthalmology","article-title":"Promising therapeutic drug delivery systems for glaucoma: a comprehensive review","author":"Singh","year":"2020"},{"key":"10.1016\/j.ejpb.2025.114637_b0060","doi-asserted-by":"crossref","DOI":"10.2174\/1872211308666140926112000","article-title":"Recent patents on ophthalmic nanoformulations and therapeutic implications","volume":"8","author":"Ako-Adounvo","year":"2014","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"10.1016\/j.ejpb.2025.114637_b0065","series-title":"International Journal of Molecular Sciences","article-title":"Nanotechnology for topical drug delivery to the anterior segment of the eye","author":"Vaneev","year":"2021"},{"key":"10.1016\/j.ejpb.2025.114637_b0070","series-title":"Pharmaceutics","article-title":"Advanced Formulation Approaches for Ocular Drug Delivery: State-of-the-Art and Recent Patents","author":"Souto","year":"2019"},{"issue":"4","key":"10.1016\/j.ejpb.2025.114637_b0075","first-page":"149","article-title":"New ophthalmic drug delivery systems","volume":"44","author":"Castro-Balado","year":"2020","journal-title":"Farm. Hosp."},{"key":"10.1016\/j.ejpb.2025.114637_b0080","series-title":"Experimental Eye Research","first-page":"149","article-title":"Topical drug delivery devices: A review","author":"Bertens","year":"2018"},{"key":"10.1016\/j.ejpb.2025.114637_b0085","volume":"24","author":"Ahmed","year":"2023"},{"key":"10.1016\/j.ejpb.2025.114637_b0090","first-page":"218","article-title":"Topical ocular drug delivery systems: Innovations for an unmet need","volume":"1","author":"Yang","year":"2022","journal-title":"Exp. Eye Res."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2025.114637_b0095","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ijpharm.2012.06.052","article-title":"Proteins, polysaccharides, and their complexes used as stabilizers for emulsions: alternatives to synthetic surfactants in the pharmaceutical field?","volume":"436","author":"Bouyer","year":"2012","journal-title":"Int. J. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114637_b0100","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3109\/10717544.2010.483257","article-title":"Solid lipid nanoparticles for ocular drug delivery","volume":"17","author":"Seyfoddin","year":"2010","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2025.114637_b0105","series-title":"Pharmaceutics","article-title":"Ophthalmic Drug Delivery Systems for Antibiotherapy- A Review","author":"Dubald","year":"2018"},{"key":"10.1016\/j.ejpb.2025.114637_b0110","series-title":"Gels","article-title":"Gel-Based Materials for Ophthalmic Drug Delivery","author":"Cassano","year":"2021"},{"key":"10.1016\/j.ejpb.2025.114637_b0115","series-title":"Materials Science and Engineering C","article-title":"Hydrogels-Based Ophthalmic Drug Delivery Systems for Treatment of Ocular Diseases","author":"Fang","year":"2021"},{"key":"10.1016\/j.ejpb.2025.114637_b0120","series-title":"European Journal of Pharmaceutics and Biopharmaceutics","first-page":"227","article-title":"Hydrogels in ophthalmic applications","author":"Kirchhof","year":"2015"},{"issue":"9","key":"10.1016\/j.ejpb.2025.114637_b0125","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3109\/03639045.2015.1137306","article-title":"Formulation and development of ophthalmic in situ gel for the treatment ocular inflammation and infection using application of quality by design concept","volume":"42","author":"Patel","year":"2016","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"42","key":"10.1016\/j.ejpb.2025.114637_b0130","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/aad7da","article-title":"A potential nanoparticle-loaded in situ gel for enhanced and sustained ophthalmic delivery of dexamethasone","volume":"29","author":"Wen","year":"2018","journal-title":"Nanotechnology"},{"key":"10.1016\/j.ejpb.2025.114637_b0135","series-title":"Journal of Nanobiotechnology","article-title":"Nanotechnology-based ocular drug delivery systems: recent advances and future prospects","author":"Li","year":"2023"},{"key":"10.1016\/j.ejpb.2025.114637_b0140","series-title":"European Journal of Pharmaceutical Sciences","article-title":"Current trends in pharmaceutical treatment of dry eye disease: A review","author":"Mohamed","year":"2022"},{"key":"10.1016\/j.ejpb.2025.114637_b0145","first-page":"602","article-title":"Ocular drug delivery: Present innovations and future challenges","volume":"370","author":"Gote","year":"2019"},{"key":"10.1016\/j.ejpb.2025.114637_b0150","series-title":"Eye (Basingstoke)","first-page":"1371","article-title":"Advances in Ocular Drug Delivery Systems","author":"Kang-Mieler","year":"2020"},{"issue":"4","key":"10.1016\/j.ejpb.2025.114637_b0155","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2174\/1872211314666191224115211","article-title":"Nano-based drug delivery system: recent strategies for the treatment of ocular disease and future perspective","volume":"13","author":"Qamar","year":"2019","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"10.1016\/j.ejpb.2025.114637_b0160","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.4103\/ijo.IJO_1893_22","article-title":"for ocular drug delivery: Recent advances and future opportunities","volume":"71","author":"Amrutkar","year":"2023","journal-title":"Indian Journal of Ophthalmology. Wolters Kluwer Medknow Publications"},{"key":"10.1016\/j.ejpb.2025.114637_b0165","series-title":"Advanced Drug Delivery Reviews","article-title":"Novel drug delivery systems for the management of dry eye","author":"Nagai","year":"2022"},{"issue":"1","key":"10.1016\/j.ejpb.2025.114637_b0170","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2023.2219419","article-title":"Therapeutic applications of contact lens-based drug delivery systems in ophthalmic diseases","volume":"30","author":"Zhao","year":"2023","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2025.114637_b0175","doi-asserted-by":"crossref","unstructured":"Prasad M, Lambe UP, Brar B, Shah I, J M, Ranjan K, et al. Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world. Vol. 97, Biomedicine and Pharmacotherapy. Elsevier Masson SAS; 2018. p. 1521\u201337.","DOI":"10.1016\/j.biopha.2017.11.026"},{"key":"10.1016\/j.ejpb.2025.114637_b0180","doi-asserted-by":"crossref","DOI":"10.2165\/00002018-199000051-00015","article-title":"N on-Medicinal Ingredients","volume":"Vol. 5","author":"Scott","year":"1990","journal-title":"Drug Saf."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114637_b0185","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1006\/rtph.2000.1421","article-title":"Pharmaceutical excipient development: the need for preclinical guidance","volume":"32","author":"Baldrick","year":"2000","journal-title":"Regul. Toxicol. Pharm."},{"issue":"6","key":"10.1016\/j.ejpb.2025.114637_b0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235076","article-title":"Biologic excipients: importance of clinical awareness of inactive ingredients","volume":"15","author":"Ionova","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2025.114637_b0195","doi-asserted-by":"crossref","DOI":"10.1006\/rtph.1996.0120","article-title":"A new approach to the safety assessment of pharmaceutical excipients the safety committee of the international pharmaceutical excipients council","volume":"24","author":"Steinberg","year":"1996","journal-title":"Regulatory Toxicol. Pharmacol.."},{"key":"10.1016\/j.ejpb.2025.114637_b0200","doi-asserted-by":"crossref","unstructured":"Pottel J, Armstrong D, Zou L, Fekete A, Huang XP, Torosyan H, et al. The activities of drug inactive ingredients on biological targets. 2020 Jul 23;403\u201313. Available from: http:\/\/sea16.ucsf.bkslab.org.","DOI":"10.1126\/science.aaz9906"},{"key":"10.1016\/j.ejpb.2025.114637_b0205","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1208\/s12249-011-9677-z","article-title":"Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility","volume":"12","author":"Wu","year":"2011","journal-title":"AAPS PharmSciTech"},{"issue":"10","key":"10.1016\/j.ejpb.2025.114637_b0210","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1016\/j.xphs.2018.06.004","article-title":"The value of U.S. pharmacopeial standards: a review of the literature","volume":"107","author":"Heyward","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114637_b0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jpba.2005.07.017","article-title":"Official USP reference standards: metrology concepts, overview, and scientific issues and opportunities","volume":"40","author":"Williams","year":"2006","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2025.114637_b0220","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5731\/pdajpst.2011.00634","article-title":"Excipients and their role in approved injectable products: current usage and future directions","volume":"65","author":"Nema","year":"2011","journal-title":"PDA J. Pharm. Sci. Technol."},{"issue":"87","key":"10.1016\/j.ejpb.2025.114637_b0225","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejps.2015.12.018","article-title":"Pharmaceutical excipients - quality, regulatory and biopharmaceutical considerations","volume":"25","author":"Elder","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114637_b0230","series-title":"Journal of Pharmaceutical Sciences","first-page":"2019","article-title":"An overview of pharmaceutical excipients: safe or not safe?","author":"Abrantes","year":"2016"},{"key":"10.1016\/j.ejpb.2025.114637_b0235","series-title":"International Journal of Molecular Sciences","first-page":"1","article-title":"Pharmaceutical excipients and drug metabolism: a mini-review","author":"Patel","year":"2020"},{"issue":"120","key":"10.1016\/j.ejpb.2025.114637_b0240","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejps.2018.04.032","article-title":"Biopharmaceutical evaluation of surface active ophthalmic excipients using in vitro and ex vivo corneal models","volume":"30","author":"Jureti\u0107","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114637_b0245","series-title":"Journal of Investigational Allergology and Clinical Immunology","first-page":"431","article-title":"Fundamental Aspects and Relevance of Components in Antihistamine Eye Drops","author":"Herrero-Vanrell","year":"2023"},{"issue":"9","key":"10.1016\/j.ejpb.2025.114637_b0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics11090460","article-title":"Advanced formulation approaches for ocular drug delivery: State-of-the-art and recent patents","volume":"11","author":"Souto","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114637_b0255","series-title":"Therapeutic Delivery","first-page":"1297","article-title":"Advances in ophthalmic drug delivery","author":"Morrison","year":"2014"},{"key":"10.1016\/j.ejpb.2025.114637_b0260","first-page":"310","article-title":"Cyclodextrin-enabled nepafenac eye drops with improved absorption open a new therapeutic window","volume":"15","author":"Vincze","year":"2023","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2025.114637_b0265","series-title":"Pharmaceutics","article-title":"Penetration Enhancers in Ocular Drug Delivery","author":"Moiseev","year":"2019"},{"issue":"2","key":"10.1016\/j.ejpb.2025.114637_b0270","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1021\/mp3005963","article-title":"Cyclodextrin-mediated enhancement of riboflavin solubility and corneal permeability","volume":"10","author":"Morrison","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2025.114637_b0275","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3109\/03639045.2012.736515","article-title":"Recent advances in ocular drug delivery","volume":"39","author":"Achouri","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2025.114637_b0280","series-title":"Journal of Controlled Release","first-page":"91","article-title":"Enhanced topical corticosteroids delivery to the eye: a trade-off in strategy choice","author":"Shen","year":"2021"},{"key":"10.1016\/j.ejpb.2025.114637_b0285","series-title":"International Journal of Pharmaceutics","article-title":"Progress in drug formulation design and delivery of medicinal substances used in ophthalmology","author":"Wr\u00f3blewska","year":"2021"},{"key":"10.1016\/j.ejpb.2025.114637_b0290","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14102142","article-title":"Aqueous Prostaglandin Eye Drop Formulations","volume":"Vol. 14","author":"Jansook","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114637_b0295","article-title":"Biodegradable polymers and constructs: a novel approach in drug delivery","volume":"120","author":"Prajapati","year":"2019","journal-title":"Eur. Polym. J. [Internet]."},{"issue":"1","key":"10.1016\/j.ejpb.2025.114637_b0300","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1080\/10717544.2021.1938756","article-title":"PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application","volume":"28","author":"Su","year":"2021","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2025.114637_b0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2020.01.057","article-title":"Advances and limitations of drug delivery systems formulated as eye drops","volume":"321","author":"Jumelle","year":"2020","journal-title":"J. Controlled Release [Internet]."},{"key":"10.1016\/j.ejpb.2025.114637_b0310","series-title":"Molecular Pharmaceutics","first-page":"3719","article-title":"Ophthalmic Nanoemulsions: From Composition to Technological Processes and Quality Control","author":"Gawin-Miko\u0142ajewicz","year":"2021"},{"key":"10.1016\/j.ejpb.2025.114637_b0315","doi-asserted-by":"crossref","unstructured":"Zambito Y, Di Colo G. Chitosan and its derivatives as intraocular penetration enhancers. Vol. 20. 2010.","DOI":"10.1016\/S1773-2247(10)50005-4"},{"key":"10.1016\/j.ejpb.2025.114637_b0320","unstructured":"Barabino S, Benitez-Del-Castillo JM, Fuchsluger T, Labetoulle M, Malachkova N, Meloni M, et al. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification."},{"key":"10.1016\/j.ejpb.2025.114637_b0325","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1081\/DDC-120003445","article-title":"Ocular preparations: the formulation approach","volume":"28","author":"Kaur","year":"2002","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2025.114637_b0330","doi-asserted-by":"crossref","first-page":"71","DOI":"10.17219\/pim\/166413","article-title":"A review on topical ophthalmic drug delivery system: reference to viscosity enhancer","volume":"54","author":"Pawar","year":"2024","journal-title":"Polim. Med."},{"key":"10.1016\/j.ejpb.2025.114637_b0335","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1517\/17425247.2013.796360","article-title":"Applications of poloxamers in ophthalmic pharmaceutical formulations: an overview","volume":"10","author":"Almeida","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2025.114637_b0340","series-title":"Pharmaceutics","article-title":"Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma","author":"Albarqi","year":"2023"},{"key":"10.1016\/j.ejpb.2025.114637_b0345","series-title":"Advances in Colloid and Interface Science","article-title":"Strategies to prolong the residence time of drug delivery systems on ocular surface","author":"Grassiri","year":"2021"},{"key":"10.1016\/j.ejpb.2025.114637_b0350","series-title":"Clinical Ophthalmology","first-page":"3883","article-title":"Safe and Effective Management of Dry Eye Symptoms with Hydroxypropyl Guar and Hyaluronic Acid Dual-Polymer Lubricating Eye Drops: A Review of Preclinical and Clinical Studies","author":"Srinivasan","year":"2023"},{"key":"10.1016\/j.ejpb.2025.114637_b0355","series-title":"International Journal of Molecular Sciences","article-title":"Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease","author":"Labetoulle","year":"2022"},{"key":"10.1016\/j.ejpb.2025.114637_b0360","series-title":"Current Opinion in Allergy and Clinical Immunology","first-page":"382","article-title":"Ocular surface lubricants","author":"Bielory","year":"2017"},{"issue":"8","key":"10.1016\/j.ejpb.2025.114637_b0365","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/aos.15159","article-title":"Hyaluronic acid in the treatment of dry eye disease","volume":"100","author":"Hynnekleiv","year":"2022","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.ejpb.2025.114637_b0370","series-title":"International Journal of Environmental Research and Public Health","first-page":"1","article-title":"A meta-analysis of the efficacy of hyaluronic acid eye drops for the treatment of dry eye syndrome","author":"Yang","year":"2021"},{"key":"10.1016\/j.ejpb.2025.114637_b0375","series-title":"Pharmaceutics","article-title":"Poloxamer Hydrogels for Biomedical Applications","author":"Russo","year":"2019"},{"key":"10.1016\/j.ejpb.2025.114637_b0380","series-title":"International Journal of Biological Macromolecules","article-title":"A review on revolutionizing ophthalmic therapy: Unveiling the potential of chitosan, hyaluronic acid, cellulose, cyclodextrin, and poloxamer in eye disease treatments","author":"Wang","year":"2024"},{"key":"10.1016\/j.ejpb.2025.114637_b0385","series-title":"Therapeutic Delivery. Newlands Press Ltd","first-page":"435","article-title":"Recent advances in ophthalmic drug delivery","author":"Kompella","year":"2010"},{"key":"10.1016\/j.ejpb.2025.114637_b0390","series-title":"Pharmaceutics","article-title":"Biopolymers in Mucoadhesive Eye Drops for Treatment of Dry Eye and Allergic Conditions: Application and Perspectives","author":"Ra\u010di\u0107","year":"2023"},{"key":"10.1016\/j.ejpb.2025.114637_b0395","series-title":"Advanced Drug Delivery Reviews","article-title":"Ocular therapies with biomacromolecules: From local injection to eyedrop and emerging noninvasive delivery strategies","author":"Fan","year":"2023"},{"issue":"5","key":"10.1016\/j.ejpb.2025.114637_b0400","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/jps.21043","article-title":"Polymeric enhancers of mucosal epithelia permeability: synthesis, transepithelial penetration-enhancing properties, mechanism of action, safety issues","volume":"97","author":"Di Colo","year":"2008","journal-title":"J. Pharm. Sci."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2025.114637_b0405","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2014.06.007","article-title":"Enhancement in corneal permeability of riboflavin using calcium sequestering compounds","volume":"472","author":"Morrison","year":"2014","journal-title":"Int. J. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2025.114637_b0410","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijpharm.2004.11.019","article-title":"Synergistic effect of EDTA and boric acid on corneal penetration of CS-088","volume":"290","author":"Kikuchi","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114637_b0415","series-title":"International Journal of Molecular Sciences","article-title":"The role of inflammation in retinal neurodegeneration and degenerative diseases","author":"Kaur","year":"2022"},{"key":"10.1016\/j.ejpb.2025.114637_b0420","unstructured":"Sheppard JD, Evans DG, Protzko EE. A Review of the First Anti-Evaporative Prescription Treatment for Dry Eye Disease: Perfluorohexyloctane Ophthalmic Solution [Internet]. 2023. www.ajmc.com."},{"issue":"5","key":"10.1016\/j.ejpb.2025.114637_b0425","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ophtha.2022.12.021","article-title":"NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study","volume":"130","author":"Tauber","year":"2023","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ejpb.2025.114637_b0430","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/jop.2019.0092","article-title":"Influence of perfluorohexyloctane eye drops on tear film thickness in patients with mild to moderate dry eye disease: a randomized controlled clinical trial","volume":"36","author":"Schmidl","year":"2020","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2025.114637_b0435","series-title":"Ocular Surface","first-page":"254","article-title":"Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent","author":"Ballesteros-S\u00e1nchez","year":"2023"},{"key":"10.1016\/j.ejpb.2025.114637_b0440","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000489513","article-title":"Buffering capacity","volume":"54","author":"Proksch","year":"2018","journal-title":"Cur. Prob. Dermatol. (Switzerland)."},{"key":"10.1016\/j.ejpb.2025.114637_b0445","doi-asserted-by":"crossref","unstructured":"Schuerer N, Stein E, Inic-Kanada A, Pucher M, Hohenadl C, Bintner N, et al. Implications for Ophthalmic Formulations: Ocular Buffers Show Varied Cytotoxic Impact on Human Corneal-Limbal and Human Conjunctival Epithelial Cells [Internet]. 2017. Available from: www.corneajrnl.com.","DOI":"10.1097\/ICO.0000000000001199"},{"issue":"10","key":"10.1016\/j.ejpb.2025.114637_b0450","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1089\/jop.2014.0054","article-title":"Corneal calcification and phosphates: Do you need to prescribe phosphate free?","volume":"30","author":"Popiela","year":"2014","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.ejpb.2025.114637_b0455","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1136\/bjo.2009.177386","article-title":"Changing the composition of buffered eye-drops prevents undesired side effects","volume":"94","author":"Schrage","year":"2010","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2025.114637_b0460","series-title":"Journal of Pharmaceutical Sciences","first-page":"2375","article-title":"Boric acid, a Lewis acid with unique and unusual properties: formulation implications","author":"Lopalco","year":"2020"},{"key":"10.1016\/j.ejpb.2025.114637_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.clae.2010.06.010","article-title":"Nonclinical safety evaluation of boric acid and a novel borate-buffered contact lens multi-purpose solution, Biotrue\u2122 multi-purpose solution","volume":"33","author":"Lehmann","year":"2010","journal-title":"Contact Lens and Anterior Eye"},{"key":"10.1016\/j.ejpb.2025.114637_b0470","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2018.06.031","article-title":"Polymer-based carriers for ophthalmic drug delivery","volume":"285","author":"Imperiale","year":"2018","journal-title":"J. Control. Release [Internet]"},{"key":"10.1016\/j.ejpb.2025.114637_b0475","first-page":"3","article-title":"Parabens","volume":"30","author":"Fransway","year":"2019"},{"issue":"1","key":"10.1016\/j.ejpb.2025.114637_b0480","first-page":"2","article-title":"Preservatives from the eye drops and the ocular surface","volume":"59","author":"Mihaela Cristina","year":"2015","journal-title":"Rom J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.ejpb.2025.114637_b0485","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0939-6411(01)00246-6","article-title":"Ocular tolerance of preservatives and alternatives","volume":"53","author":"Furrer","year":"2002","journal-title":"Eur. J. Pharmaceutics Biopharmaceutics [Internet]."},{"key":"10.1016\/j.ejpb.2025.114637_b0490","series-title":"British Journal of OphthalmologyBMJ Publishing Group","first-page":"1497","article-title":"Preservatives in glaucoma medication","author":"Steven","year":"2018"},{"key":"10.1016\/j.ejpb.2025.114637_b0495","series-title":"Eye (Basingstoke)","first-page":"361","article-title":"Ocular Benzalkonium Chloride Exposure: Problems and Solutions","author":"Goldstein","year":"2022"},{"key":"10.1016\/j.ejpb.2025.114637_b0500","first-page":"1","article-title":"Penetration enhancers for topical drug delivery to the ocular posterior segment \u2014 A systematic review","volume":"13","author":"Thareja","year":"2021","journal-title":"Pharmaceutics. MDPI AG"},{"issue":"S278","key":"10.1016\/j.ejpb.2025.114637_b0505","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/aos.15808","article-title":"The use of benzalkonium chloride in topical glaucoma treatment","volume":"101","author":"Nagstrup","year":"2023","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.ejpb.2025.114637_b0510","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.2147\/OPTH.S431889","article-title":"Efficacy and toxicity evaluation of bepotastine besilate 1.5% preservative-free eye drops vs olopatadine hydrochloride 0.2% Bak-preserved eye drops in patients with allergic conjunctivitis","volume":"17","author":"Marini","year":"2023","journal-title":"Clin. Ophthalmol."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114637_b0515","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000517845","article-title":"Benzalkonium chloride-preserved anti-glaucomatous eye drops and their effect on human conjunctival goblet cells in vitro","volume":"6","author":"Hedengran","year":"2021","journal-title":"Biomed. Hub"},{"issue":"319","key":"10.1016\/j.ejpb.2025.114637_b0520","first-page":"84","article-title":"Benzalkonium chloride-induced direct and indirect toxicity on corneal epithelial and trigeminal neuronal cells: proinflammatory and apoptotic responses in vitro","volume":"1","author":"Vitoux","year":"2020","journal-title":"Toxicol. Lett."},{"issue":"5","key":"10.1016\/j.ejpb.2025.114637_b0525","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1007\/s40123-023-00769-y","article-title":"Impact of latanoprost antiglaucoma eyedrops and their excipients on toxicity and healing characteristics in the ex vivo eye irritation test system","volume":"12","author":"Panfil","year":"2023","journal-title":"Ophthalmol Ther."},{"key":"10.1016\/j.ejpb.2025.114637_b0530","series-title":"Journal of Pharmaceutical and Biomedical Analysis","first-page":"122","article-title":"Applications of various analytical techniques in quality control of pharmaceutical excipients","author":"Kumar","year":"2018"},{"issue":"3","key":"10.1016\/j.ejpb.2025.114637_b0535","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.yrtph.2015.09.020","article-title":"The evolution and challenges for the international harmonization of the regulation of pharmaceutical excipients in Taiwan","volume":"73","author":"Chang","year":"2015","journal-title":"Regul. Toxicol. Pharm."},{"issue":"6","key":"10.1016\/j.ejpb.2025.114637_b0540","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2174\/0113816128285827240119095013","article-title":"Artificial Intelligence technologies used for the assessment of pharmaceutical excipients","volume":"30","author":"Kumar","year":"2024","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejpb.2025.114637_b0545","doi-asserted-by":"crossref","DOI":"10.2174\/092986706778201648","article-title":"Drug excipients","volume":"Vol. 13","author":"Kal\u00e1sz","year":"2006","journal-title":"Curr. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejpb.2025.114637_b0550","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s11095-021-03157-y","article-title":"Excipient innovation through precompetitive research","volume":"38","author":"Yu","year":"2021","journal-title":"Pharm. Res."},{"issue":"8","key":"10.1016\/j.ejpb.2025.114637_b0555","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0014-827X(03)00079-X","article-title":"The safety of pharmaceutical excipients","volume":"58","author":"Pifferi","year":"2003","journal-title":"Farmaco"},{"key":"10.1016\/j.ejpb.2025.114637_b0560","series-title":"Drug Discovery Today","first-page":"1539","article-title":"The safety evaluation of long-acting ocular delivery systems","author":"Thackaberry","year":"2019"},{"issue":"5","key":"10.1016\/j.ejpb.2025.114637_b0565","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-020-01726-9","article-title":"An Analytic Investigation of the Drug Formulation-Based Recalls in the USA: See More Beyond the Literal","volume":"21","author":"Yang","year":"2020","journal-title":"AAPS PharmSciTech."},{"issue":"8","key":"10.1016\/j.ejpb.2025.114637_b0570","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/j.jaip.2021.03.002","article-title":"Hidden Dangers: Recognizing Excipients as potential causes of drug and vaccine hypersensitivity reactions","volume":"9","author":"Caballero","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"5","key":"10.1016\/j.ejpb.2025.114637_b0575","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1684\/ejd.2022.4291","article-title":"Do generic drugs cause hypersensitivity?","volume":"32","author":"Tetart","year":"2022","journal-title":"Eur. J. Dermatol."},{"issue":"483","key":"10.1016\/j.ejpb.2025.114637_b0580","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau6753","article-title":"Inactive ingredients in oral medications","volume":"11","author":"Reker","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.ejpb.2025.114637_b0585","doi-asserted-by":"crossref","first-page":"400","DOI":"10.18176\/jiaci.0562","article-title":"Delayed hypersensitivity reactions caused by drug excipients: a literature review","volume":"30","author":"Caballero","year":"2020","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"10.1016\/j.ejpb.2025.114637_b0590","series-title":"Journal of Investigational Allergology and Clinical Immunology","first-page":"86","article-title":"Immediate hypersensitivity reactions caused by drug excipients: A literature review","author":"Caballero","year":"2020"},{"key":"10.1016\/j.ejpb.2025.114637_b0595","series-title":"Drug Development and Industrial Pharmacy","first-page":"1565","article-title":"Excipients in parenteral formulations: selection considerations and effective utilization with small molecules and biologics","author":"Rayaprolu","year":"2018"},{"key":"10.1016\/j.ejpb.2025.114637_b0600","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/109158180302200506","article-title":"The Use of Unallowed Excipients","volume":"22","author":"Steinberg","year":"2003","journal-title":"Int J Toxicol [internet]."},{"key":"10.1016\/j.ejpb.2025.114637_b0605","series-title":"Therapeutic Delivery","first-page":"949","article-title":"Case studies with new excipients: Development, implementation and regulatory approval","author":"Koo","year":"2011"},{"key":"10.1016\/j.ejpb.2025.114637_b0610","series-title":"Advanced Drug Delivery Reviews","first-page":"23","article-title":"Nanomedicines - tiny particles and big challenges","author":"Marques","year":"2019"},{"key":"10.1016\/j.ejpb.2025.114637_b0615","series-title":"Drug Development and Industrial Pharmacy","first-page":"1735","article-title":"Bridging the gap: academia, industry and FDA convergence for nanomaterials","author":"Shah","year":"2020"},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2025.114637_b0620","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijpharm.2015.01.022","article-title":"Excipient pharmacokinetics and profiling","volume":"480","author":"Loftsson","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ejpb.2025.114637_b0625","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.yrtph.2011.02.010","article-title":"Excipients in medicinal products used in gastroenterology as a possible cause of side effects","volume":"60","author":"Ursino","year":"2011","journal-title":"Regul. Toxicol. Pharm."},{"key":"10.1016\/j.ejpb.2025.114637_b0630","first-page":"269","article-title":"Development of new excipients","volume":"1","author":"Kolter","year":"2017","journal-title":"Pharmaceutical Excipients: Properties, Functionality, and Applications in Research and Industry."},{"issue":"3","key":"10.1016\/j.ejpb.2025.114637_b0635","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/cpt.458","article-title":"A molecular basis for innovation in drug excipients","volume":"101","author":"Irwin","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2025.114637_b0640","first-page":"361","article-title":"ICH M9 Guideline in Development on Biopharmaceutics Classification System-Based Biowaivers: An Industrial Perspective from the IQ Consortium, Molecular Pharmaceutics","volume":"17","author":"Bransford","year":"2020","journal-title":"American Chemical Society"},{"key":"10.1016\/j.ejpb.2025.114637_b0645","first-page":"595","article-title":"ICH Guidelines-Implementation of the 3Rs (Refinement, Reduction, and Replacement): incorporating Best Scientific Practices into the Regulatory Process","volume":"43","author":"Ohno","year":"2002","journal-title":"ILAR J [internet]."},{"issue":"6","key":"10.1016\/j.ejpb.2025.114637_b0650","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-021-00657-y","article-title":"ICH Q10 pharmaceutical quality system guidance: understanding its impact on pharmaceutical quality","volume":"23","author":"VanDuyse","year":"2021","journal-title":"AAPS J."},{"issue":"9","key":"10.1016\/j.ejpb.2025.114637_b0655","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.xphs.2018.04.009","article-title":"An elemental impurities excipient database: a viable tool for ICH Q3D drug product risk assessment","volume":"107","author":"Boetzel","year":"2018","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.ejpb.2025.114637_b0660","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.xphs.2021.10.012","article-title":"ICH Q3D drug product elemental risk assessment: the use of an elemental impurities excipients database","volume":"111","author":"Torres","year":"2022","journal-title":"J. Pharm. Sci."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112500013X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112500013X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:41:19Z","timestamp":1762332079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093964112500013X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":132,"alternative-id":["S093964112500013X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114637","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Excipients in drug delivery systems: A comprehensive review of approved inactive ingredients for human ophthalmic formulations","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114637","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114637"}}